Ntla stock forecast.

Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $1.41. This compares to loss of $1.96 per share a year ago.

Ntla stock forecast. Things To Know About Ntla stock forecast.

NTLA Stock 12 Months Forecast. Based on 19 Wall Street analysts offering 12 month price targets for Intellia Therapeutics in the last 3 months. The average price target is $78.65 with a high forecast of $136.00 and a low forecast of $31.00. The average price target represents a 151.68% change from the last price of $31.25.The U.S. National Weather Service (NWS) is a part of the National Oceanic and Atmospheric Administration (NOAA). Many people rely on the National Weather Service’s forecasts in order to better anticipate what the weather will be like so the...١٨‏/٠٤‏/٢٠٢٣ ... Analysts are bullish on NTLA stock. It currently has a mean price ... price and institutional investors own approximately 85% of the stock.According to 11 Wall Street analyst s that have issued a 1 year NTLA price target, the average NTLA price target is $77.46, with the highest NTLA stock price forecast at …Gov.capital. Intellia Therapeutics (NTLA) stock price prediction is 94.108148888185 USD. The Intellia Therapeutics stock forecast is 94.108148888185 …

Discover historical prices for NTLA stock on Yahoo Finance. View daily, weekly or monthly format back to when Intellia Therapeutics, Inc. stock was issued.

Editas Medicine has undergone some internal restructuring in Q1 2023, with strategic reprioritization focusing on hemoglobinopathies and in vivo gene editing. A competitor to CRISPR Therapeutics, the company is currently working on EDIT-301 for SCD and TDT as well. Unlike CRISPR’s product, EDIT-301 uses AsCas12a to edit the …As for NTLA-2002, the company plans to kick off the Phase 2 segment of the ongoing Phase 1/2 study during the first half of the year. An IND to get U.S. sites included in the Phase 2 study of NTLA ...

Nov 14, 2023 · Future criteria checks 2/6. Intellia Therapeutics is forecast to grow earnings and revenue by 6.3% and 57.2% per annum respectively. EPS is expected to grow by 11.3% per annum. Return on equity is forecast to be -20.1% in 3 years. The average TDOC stock price target stood at $124.77 a share, resulting in a potential 64% upside based on the last closing price of $75.86 (as of 28 February). The highest 12-month Teladoc share price forecast was $215, while the lowest was set at $67. Right after the company announced its results for the fourth quarter of the 2021 fiscal …Planning a trip can be an exciting but challenging task. From booking accommodations to creating an itinerary, there are countless details to consider. One crucial aspect that should never be overlooked is checking the 7-day weather forecas...Intellia Therapeutics Stock Chart and Share Price Forecast, Short-Term "NTLA" Stock Prediction for Next Days and Weeks Walletinvestor.com Intellia Therapeutics Inc (NTLA) Forecast Chart, Long-Term Predictions for Next Months and Year: 2023, 2024 Find the latest Caribou Biosciences, Inc. (CRBU) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Performance Outlook. Short Term. 2W ...

Intellia Therapeutics Inc’s Stock Price as of Market Close. As of March 22, 2023, 4:00 PM CST, Intellia Therapeutics Inc’s stock price was $37.15. Intellia Therapeutics Inc is down 6.63% from its previous closing price of $39.79. During the last market session, Intellia Therapeutics Inc’s stock traded between $38.25 and $39.94.

Analyst Forecast According to 21 analysts, the average rating for NTLA stock is "Buy." The 12-month stock price forecast is $77.4, which is an increase of 161.22% from the latest price.

Intellia has declined in the double digits over the past year. Superstar investor Cathie Wood is increasing her bet on a cutting-edge technology that could transform the treatment of many diseases ...NTLA is a biotech company that develops gene editing therapies for cancer and other diseases. The average price target for its stock is $82.19, with a range of $40 to $144, based on 21 analyst recommendations. The stock has a strong buy rating from 18 brokerage firms and a low of 40.00. The upside is 237.12%.Jul 27, 2023 · Read why NTLA stock is a Buy. Intellia is a pipeline-stage firm, leveraging gene-editing technology to develop therapies for rare diseases. ... So, I forecast NTLA’s cash flow statement using ... Nov 30, 2023 · Stock Price Forecast. According to 20 stock analysts, the average 12-month stock price forecast for NTLA stock stock is $77.4, which predicts an increase of 149.44%. The lowest target is $39 and the highest is $136. On average, analysts rate NTLA stock stock as a buy. Intellia Therapeutics (NTLA) Stock Forecast & Price Prediction. Estimation of the future price movement of Intellia Therapeutics stock, based on various factors such as historical price trends, market trends, company performance, and economic conditions.We've seen plenty of personal finance tools designed to help you track what you're spending, but web site PocketSmith is an impressive new web-based personal finance tool with an emphasis on forecasting your financial future. We've seen ple...There was a snowstorm in the Northeast this week. Or maybe that supposed storm was just a light dusting. It depends on who you ask. Having grown up in the mountains of Colorado, I am well aware at just how terrible these forecasts tend to b...

Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.We’ve all flipped between different weather apps, wondering why each is giving a slightly different report. Before we look at AccuWeather, it’s important to understand the basics of weather forecasting. In the past, weather predictions were...Find the latest CRISPR Therapeutics AG (CRSP) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Performance Outlook. Short Term. 2W - 6W ...The global RPA market reached $2.3 billion in 2022, and Grand View Research forecasts that it will grow at an annualized rate of 39.3% from 2023 through 2030. If you want to follow Wood and buy ...Intellia Therapeutics last announced its quarterly earnings results on November 9th, 2023. The reported ($1.38) earnings per share for the quarter, topping the consensus estimate of ($1.52) by $0.14. The business earned $11.99 million during the quarter, compared to the consensus estimate of $12.45 million.(See NTLA stock forecast on TipRanks) PDS Biotechnology . The next stock on Oppenheimer's radar is another biopharma company, PDS Biotechnology. PDS has a research program focuses on immuno ...The average Marvell Technology stock price prediction forecasts a potential upside of 25.7% from the current MRVL share price of $56.03. What is MRVL's forecast return on equity (ROE) for 2024-2026? (NASDAQ: MRVL) forecast ROE is …

The 24 analysts offering 12-month price forecasts for Intellia Therapeutics Inc have a median target of 72.00, with a high estimate of 145.00 and a low estimate of 29.00. The median estimate represents a +137.08% increase from the last price of 30.37. The current consensus among 27 polled investment analysts is to Buy stock in Intellia ...

Intellia Therapeutics ( NASDAQ: NTLA) added ~13% on Thursday to reach the highest level in more than two months after the gene-editing company reported its Q1 2023 financials alongside updates ...In the world of business, cash flow is king. Having a clear understanding of your company’s cash flow is essential for making informed financial decisions and ensuring the long-term success of your business.That revenue goes along with positive earnings per share of $12.83 in 2022. And the forecast is that Vertex will grow earnings in 2023. What makes Vertex a potential high-growth biotech stock in ...But Intellia has two programs in early-stage trials that could make this a monster stock in the future. NTLA-2001 is an in vivo gene-editing treatment for transthyretin amyloidosis, a condition ...Oct 6, 2020 · For Intellia Therapeutics stock forecast for 2023, 2 predictions are offered for each month of 2023 with average Intellia Therapeutics stock forecast of $23.66, a high forecast of $23.9, and a low forecast of $23.43. The average Intellia Therapeutics stock forecast 2023 represents a 2.17% increase from the last price of $23.1599998474121. Stock Price Forecast. The 25 analysts offering 12-month price forecasts for Gilead Sciences Inc have a median target of 90.10, with a high estimate of 116.00 and a low estimate of 71.00. The ...A high-level overview of Intellia Therapeutics, Inc. (NTLA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Nov 24, 2023 · The Intellia Therapeutics Inc stock price gained 2.54% on the last trading day (Friday, 24th Nov 2023), rising from $30.26 to $31.03. During the last trading day the stock fluctuated 5.87% from a day low at $30.13 to a day high of $31.90. The price has risen in 6 of the last 10 days and is up by 24.32% over the past 2 weeks. Future criteria checks 2/6. Intellia Therapeutics is forecast to grow earnings and revenue by 6.3% and 57.2% per annum respectively. EPS is expected to grow by 11.3% per annum. Return on equity is forecast to be -20.1% in 3 years.Nov 30, 2023 · According to 2 stock analysts, the average 12-month stock price forecast for DNA stock stock is $1.88, which predicts an increase of 45.74%. The lowest target is $1.25 and the highest is $2.50. On average, analysts rate DNA stock stock as a sell.

This stock has a credible chance of climbing, if not soaring. ... In the same period, the company plans to submit an IND for NTLA-3001, its therapy for alpha-1 antitrypsin deficiency-related lung ...

Intellia Therapeutics, Inc. CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing ...

Intellia Therapeutics, Inc. CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing ...See Intellia Therapeutics, Inc. (NTLA) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Nov 29, 2023 · See the latest Intellia Therapeutics Inc stock price (NTLA:XNAS), related news, valuation, dividends and more to help you make your investing decisions. Track Intellia Therapeutics Inc (NTLA) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors Intellia Therapeutics last announced its quarterly earnings results on November 9th, 2023. The reported ($1.38) earnings per share for the quarter, topping the consensus estimate of ($1.52) by $0.14. The business earned $11.99 million during the quarter, compared to the consensus estimate of $12.45 million.EXEL : EXELIXIS INC stock forecast by Wall Street Analysts. The average EXELIXIS INC stock forecast from last 6 month is $25.28, and this show a 7.89% increase in average from the prior price target of the each prediction. Also, this average forecast of $25.28 represents a 1.73% increase from the past average forecast of $24.85, 6 months ago from 13 wall …The average twelve-month price prediction for Intellia Therapeutics is $77.70 with a high price target of $136.00 and a low price target of $40.00. Learn more on NTLA's analyst rating history. Do Wall Street analysts like Intellia Therapeutics more than its competitors?Find real-time CRSP - CRISPR Therapeutics AG stock quotes, company profile, news and forecasts from CNN Business.

As of March 29, 2023, 4:00 PM CST, Intellia Therapeutics Inc’s stock price was $37.56. Intellia Therapeutics Inc is up 4.28% from its previous closing price of $36.02. During the last market session, Intellia Therapeutics Inc’s stock traded between $35.98 and $37.55. Currently, there are 81.26 million shares of Intellia Therapeutics Inc ...2014. 598. John Leonard. https://www.intelliatx.com. Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary ...NTLA Stock 12 Months Forecast. Based on 19 Wall Street analysts offering 12 month price targets for Intellia Therapeutics in the last 3 months. The average price target is $78.65 with a high forecast of $136.00 and a low forecast of $31.00. The average price target represents a 151.68% change from the last price of $31.25. Instagram:https://instagram. presentation courses online1979 silver dollar worth todayd stock dividendberkshire hathaway's portfolio View Intellia Therapeutics, Inc NTLA investment & stock information. Get the latest Intellia Therapeutics, Inc NTLA detailed stock quotes, stock data, Real-Time ECN, charts, stats and...Analyst Forecast According to 21 analysts, the average rating for NTLA stock is "Buy." The 12-month stock price forecast is $77.4, which is an increase of 161.22% from the latest price. stocks gainers todaythe maidan Three Fool.com contributors identified what they believe could be monster stocks in the making. Here's why these chose Axsome Therapeutics ( AXSM 0.90%), CRISPR Therapeutics ( CRSP -3.42%), and ...Real time Intellia Therapeutics (NTLA) stock price quote, stock graph, news & analysis. health insurance companies georgia The race to develop a new gene therapy with CRISPR took some interesting turns recently. On the same day that Intellia Therapeutics (NTLA-1.23%) dazzled the medical community with clinical trial ...Find real-time NTLA - Intellia Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business.